Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.

Clinical pharmacology and therapeutics - 1 Oct 2005

Perini Jamila A, Vianna-Jorge Rosane, Brogliato Ariane R, Suarez-Kurtz Guilherme

Abstract excerpt

OBJECTIVE: Our objective was to evaluate the influence of cytochrome P450 (CYP) 2C9 polymorphisms on the pharmacokinetics and pharmacodynamics of the nonsteroidal anti-inflammatory drug piroxicam. METHODS: Thirty-five healthy subjects with CYP2C9 genotypes *1/*1 (n=17), *1/*2 (n=9), and *1/*3 (n=...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Area Under Curve
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclooxygenase 1

Share to Cytochrome P-450 CYP2C9

Share to Membrane Proteins

Share to Metabolic Clearance Rate

Share to Prostaglandin-Endoperoxide Synthases

Source

Identifiers

PMID: 16198655
DOI: 10.1016/j.clpt.2005.06.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16198655-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.PMID 16198655Read ↗

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.Semantic proximity Read ↗

Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model.Semantic proximity Read ↗

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population.Semantic proximity Read ↗

Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug PrescriptionSemantic proximity Read ↗

Effect of the CYP2C9*3 allele on lornoxicam metabolism.Semantic proximity Read ↗

Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.Semantic proximity Read ↗

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.Semantic proximity Read ↗

Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?Semantic proximity Read ↗

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.